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14-3-3 proteins are apparently ubiquitous eukaryotic proteins that comprise a large number of isoforms. They have been implicated in the regulation 
of a wide range of biological processes [reviewed in Aitken et al. (1992) Trends B&hem. Sci. 17,498-5011. We have raised specific antibodies against 
each mammalian brain isoform of 14-3-3 employing peptides synthesised from the amino-terminal regions. The peptides were, like the proteins 
from mammalian brain, N-acetylated. The antiserum specific for the epsilon isofonn did not recognise the recombinant form of this protein (lacking 
the N-acetyl co-translational modification) expressed in E. coli until it was chemically acetylated. 
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1. INTRODUCTION 
The family of proteins known as 14-3-3 was so named 
due to their migration position on two dimensional gel 
electrophoresis [l]. 14-3-3 proteins all have a p1 of 
around 4.5 and M, of 30,000 Da on SDS-PAGE but 
60,000 on size exclusion chromatography [2]. There are 
seven to eight mammalian brain isoforms of 14-3-3, 
named cl_r after their respective elution positions on 
HPLC [3]. Five of these have been sequenced (reviewed 
in [4]). Clones for other HPLC separated brain 14-3-3 
proteins have not so far been identified and we present 
evidence to suggest that in two cases this may be due to 
identity of the protein primary structures with /I and 6 
(zeta) isoforms. 14-3-3 has been studied as an activator 
of tyrosine and tryptophan hydroxylases [5], the rate 
limiting step in catecholamine and serotonin neuro- 
transmitter synthesis in neurons. However, purified 
sheep brain 14-3-3 isoforms have been shown not to 
activate recombinant yrosine hydroxylase (Sutherland, 
C. et al. (1993) Eur. J. Biochem., in press). The studies 
of our own group have focussed on 14-3-3 as a anase 
C Inhibitor Protein [2,6] that we named KCIP-1. A -- 
14-3-3 protein member(s) called EXOl stimulates cal- 
cium dependent exocytosis in permeabilized adrenal 
medulla cells [7]. The epsilon (E) isoform of 14-3-3 copu- 
rifies with rat pineal N-acetyl transferase, the first en- 
zyme in the pathway for conversion of serotonin to 
melatonin [8], thereby suggesting a function for 14-3-3 
in regulating diurnal rhythm. The eukaryotic host fac- 
tor that activates exoenzyme S from Pseudomona aerug- 
*Corresponding author. Fax: (44) (81) 906 4477. 
inosa has been shown to be a member of the 14-3-3 
family (the 6 isoform, [9]). Exoenzyme S ADP-ribosyl- 
ates Ras and other GTP-binding proteins. A platelet 
phospholipase A, was identified as 14-3-3 [ isoform [lo] 
but recent studies [I 11; Robinson and Aitken (in prepa- 
ration) have found no PLA, activity in 5 or other 
isoforms of 14-3-3. Examples of 14-3-3 proteins have 
also been found in plants [12,13], insects [14] amphibi- 
ans [ 151 and yeast [ 161. In these non-mammalian species, 
a variety of roles for regulation of gene expression have 
been suggested, (reviewed in [4]). More recently, addi- 
tional evidence for a role in regulation of transcription 
has come from the group of Ferl [17] who have shown 
that a plant 14-3-3 homologue binds to the G-box pro- 
moter element of inducible genes. In some mammalian 
tissues, novel isoforms may be expressed at high level. 
T-cells contain an isoform [18] that is not a major brain 
isoform. Epithelial cells contain a specific isoform called 
HMEl [19] or stratifin [20]. In keeping with the estab- 
lished nomenclature for mammalian 14-3-3 isoforms, 
employing Greek letters, we have named the T-cell 
isoform, tau (r) and HMEl or stratifin isoform, sigma 
(6). In the present study, antisera were raised against 
synthetic peptides based on the amino terminal regions 
of mammalian 14-3-3 isoforms. The peptides were syn- 
thesised with the correct processing of the initiator 
methionine including N-acetylation of the next residue 
if appropriate. The results indicate that the antisera will 
prove to be excellent ools for the study of cellular local- 
isation and distribution of 14-3-3 isoforms since the 
antisera were distinct for each isoform. An interesting 
and important observation was made with the antise- 
rum raised against the amino terminus of the E 14-3-3 
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isoform - this was specific for the wild type N-acetyl- 
ated protein and did not recognise the identical (in lin- 
ear amino acid sequence) recombinant protein. How- 
ever, the latter protein was recognised by the antiserum 
when chemically acetylated on the initiator methionine. 
This could be an important point to note if expression 
libraries are screened using antibodies that may be spe- 
cific for N-acetylated or other co- or post-translation- 
ally modified proteins. 
using KLH as a carrier. All antigens were injected subcutaneously 
with Freund’s adjuvant. 
2.5. SDS polyacrylamide gel electrophoresis 
Proteins were run on 12.5% SDS polyacrylamide gels containing 
SDS [21] and visualised by Coomassie blue and/or silver staining [22]. 
2.6. Western blotting 
2. MATERIALS AND METHODS 
2.1. Materials 
Reagents were analytical reagent grade from Sigma or BDH. Tryp- 
sin was obtained from Boehringer Mannheim, and phosphatidylserine 
was supplied by Sigma. BNPS skatole was from Pierce. Acetonitrile 
and TFA (both HPLC grade) were from Romil and Pierce respec- 
tively. Nitrocellulose (Schleicher and Schuel) and immobilon PVDF 
membrane (Millipore) were used for electroblotting except for the 
acetylation experiment when Problott (Applied Biosystems) was used. 
Recombinant epsilon (.s) and T cell (r) isoforms of 14-3-3 were ex- 
pressed in E. coli (in preparation). 
2.2. 14-3-3 PuriJication 
14-3-3 was isolated from sheep brain by a combination of anion- 
exchange and hydrophobic-interaction chromatography steps by a 
method previously described [6]. Homogeneity was confirmed by the 
absence of other silver staining proteins on analysis of a heavy loading 
of protein (30 pg). 
The antisera were tested by immunoblotting 14-3-3 proteins from 
SDS-PAGE onto nitrocellulose [23] using a semi-dry blotting appara- 
tus (LKB 2117-250 Novablot). The SDS polyacrylamide gel was 
soaked for 40 mins in 3-cyclohexyl amino propane-sulfonic acid 
(CAPS, pH 1 1), 10% methanol transfer buffer. Transfer was carried 
out at room temperature at 2 W per 100 cm2 of gel for 2 h. The gel 
was stained with Coomassie blue to confirm that transfer had oc- 
curred. The nitrocellulose was blocked using 2.5% non-fat-l% milk 
protein in Tris-buffered saline (20 mM, pH 7.6, TBS) for 1 h. Primary 
and secondary antibodies were used at dilutions of ‘/,,ooo with the 
exception of gamma, at a dilution of ‘/6,000. Non-specifically bound 
primary antibody was washed off with 5 x 200 ml changes of Tris- 
buffered saline, 0.1% NP40 (TBSNP40) every 10 min. Peroxidase- 
coupled goat anti-rabbit IgG (Biorad) in TBS, NP40 was used as 
detecting antibody. Non-specifically bound secondary antibody was 
removed, as for the primary antibody wash and antigens were visual- 
ised with the enhanced chemiluminescence (ECL) detection system 
(Amersham, UK) and exposed to X-OMAT-AR him. Isoforms of 
14-3-3 separated by reverse phase HPLC, were blotted onto immo- 
bilon PVDF membrane after SDS PAGE and immunodetected in a 
similar manner. 
2.7. Stripping of immobilon membranes 
2.3. Reverse-phase separation of 14-3-3 
Purified preparations of 14-3-3 (500 pg) were applied to a reverse- 
phase HPLC column (Aquapore RP300, 100 mm x 2.1 mm, 7 p, 
Brownlee), [6]. Proteins were eluted by the application of a three-step 
gradient of 0.1% aqueous trifluoroacetic acid to acetonitrile (contain- 
ing 0.082% by vol. trifluoroacetic acid), with a flow rate of 0.25 
mlmin-‘. The acetonitrile concentration was increased as follows: 
0115% over 10 mins, 4560% over 85 mins, 60-90% over 10 mins. A 
100 x 4.6 mm column with a flow rate of 0.5 mlmin-’ was also used 
for larger scale (500 pg) separation of isoforms for amino acid se- 
quencing. Peaks (A& were collected manually. Samples were concen- 
trated and analysed by SDS PAGE and visualized by Coomassie blue 
or Western blotted. 
The membrane was submerged in 100 mM 2-mercaptoethanol2% 
SDS, 62.5 mM Tris-HCl, pH 6.7 and incubated at 5O’C for 8 h with 
occasional agitation. The membrane was washed 4 x 10 min in TBSl 
0.1% NP40 at room temperature using 400 ml of buffer. The mem- 
brane was reprobed with secondary antibody and incubated with ECL 
detection reagents to ensure complete removal of primary antibody 
had occurred before reprobing with the next antiserum. 
2.8. Sequence analysis 
2.8.1. Protein Cleavage 
2.4. Immunological procedures 
Antibodies against the acetylated N-terminal sequences of sheep 
14-3-3 isoforms were raised in rabbits. Acetylated peptides were pro- 
duced by Peter Fletcher in the peptide synthesis ervice at NIMR using 
an Applied Biosystems 430A peptide synthesiser and FMOC chemis- 
try. The peptides synthesised were: 
Sequence analysis was performed on peptides from both cyanogen 
bromide, CNBr [24] and BNPS-skatole [25] digests of purified 14-3-3 
isoforms. Samples for cleavage with CNBr were reduced with 0.2 M 
2-mercaptoethanol(2 h at 30°C), lyophilised and redissolved in 50% 
v/v formic acid containing CNBr (approximately loo-fold excess over 
methionine residues). The samples were incubated under nitrogen for 
24 h at 4OC in the dark. The solution was diluted to 5% formic acid 
and lyophilised. BNPS-skatole digestion was carried out in the pres- 
ence of a lOO-fold excess of reagent in glacial acetic acid for 4 h at 
47OC. The reagent was removed by ether extraction. 
2.8.2. Peptide purification and sequencing 
beta (~9,) isoform Ac.MDKSELVQKAC 
gamma (y) isoform AcVDREQLVQKAC 
zeta isoform (0 AcMDKNELVQKAC 
epsilon isofotm (c) AcMDDREDLVYQAK 
eta isoform (7) AcGDREQLLQRARZ 
human T cell (r) isoform AcMEKTELIQKAC 
Peptides were purified by reverse phase HPLC and the structure 
Peptides were fractionated on HPLC using a water/ acetonitrile gradi- 
ent (O-SO% in 0.1% v/v TFA) on a Vydac reverse-phase Cls column 
(25 x 0.46 cm). Peaks (A& were collected, concentrated and the pep- 
tides sequenced on Applied Biosystems 470A gas-phase and 477A 
pulsed liquid-phase protein sequencers with Applied Biosystems 120A 
on-line phenylthiohydantoin (PTH)-amino acid analysers [26]. Data 
collection and analysis were performed with an Applied Biosystems 
900A module calibrated with 25 pmol PTH-amino acid standards. 
verified by amino acid analysis and FAB mass spectrometry. 
The y, B, c and r cell peptides were synthesised with a C-terminal 2.9. Fast atom bombardment mass spectrometry 
cysteine residue, not present in the original sequences, to allow cou- Structural analysis of KCIP 1 peptides was performed by fast atom 
pling to maleimide-KLH using the inject activated immunogen conju- bombardment mass spectrometry on a VG-70 250SE mass spectrom- 
gation kit (Pierce, Rockford, IL, USA). The E and r] peptides were eter [271. Peptides were air dried to l-2 ~1 on the stainless teel probe 
coupled to KLH with 21 mM glutaraldehyde (1 mg peptide: 5 mg and mixed with 1 ~1 of thioglycerol matrix containing 1% v/v TFA. 
KLH). In addition, an antiserum to whole 14-3-3 protein was raised Spectra were recorded using multi channel analysis in the positive ion 
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mode on a VG 70-250 SE mass spectrometer at an operating voltage described above and the blot was divided into two sections. Roth were 
of 8 kV using a 30 kV caesium ion gun. The results are expressed in placed in 400 ml beakers, wetted with methanol and 5 ml of 50 mM 
average mass units (amu). Na,HPO, @H 8) added to each. 
Mass spectrometry of intact 14-3-3 proteins was carried out on a 
VG electrospray mass spectrometer. 
2.10. Acetylation with acetic anhydride 
Recombinant 14-3-3 E isoform was electroblotted from multiple 
lanes of an SDS PAGE gel onto Problott (PVDF membrane), as 
25 ~1 acetic anhydride (Sigma) were added to one section and the 
beaker shaken for 5 mins. After washing with high purity water the 
electroblot was rewetted with methanol and the procedure repeated 
three times. The conditions used permit a lower degree of acetylation 
of the ~-amino group of lysine residues although in the present study 
lysine was fortuitously present only at the C-terminus of the ~14-3-3 
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Fig. 1 Specificity of 14-3-3 antisera. (A) Elution profile of a pure preparation of sheep 14-3-3 from the reverse-phase HPLC column as described 
in Section 2. The diagonal ine represents the acetonitrile gradient. The inset underneath the HPLC profile is a 12.5% SDS PAGE analysis of each 
protein peak. The left lane contains a mixture of brain isoforms. Proteins were visualised by coomassie blue staining. (B) Western blots of the HPLC 
peaks shown in Fig. 1A. The Greek letters across the top of the strips denote the major 14-3-3 isoform eluted in the peak. The strip was incubated 
in turn with the antisera raised against he particular amino-terminal peptide sequence o to r] in descending order. The T-cell (r) protein was probed 
using a separate blot from SDS PAGE of 3 pg of protein from each HPLC peak. This gel included a similar 3 ,ug loading of recombinant T-cell 
protein (rec. r). This control verified that r isoform elutes between y and 6 14-3-3 but is not a major isoform in brain. (Depending on the exact 
timing of the manual collection of the peaks r isoform is sometimes detected only in the y peak - as in the example shown here). 
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Fig. 2. Antisera raised against he N-terminus of 14-3-3 E only recognises the acetylated protein. Lane 1 is a Coomassie blue-stained gel of partially 
purified recombinant 14-3-3 E (ret .s) while lane 3 shows a Western blot of an identical sample. Lane 2 is a Western blot of crude rat brain cytosol 
as a control. Lanes 4 and 6 are SDS PAGE and Western blot of identical samples of puritkd sheep brain 14-3-3 while lanes 5 and 7 are identical 
samples of SDS PAGE and Western blots of recombinant E 14-3-3 expressed asa fusion with maltose binding protein. This is indicated by the 
arrow. Lanes 8 and 10 are Western blots of a mixture of purified sheep brain 14-3-3. Lanes 9 and 11 are recombinant E 14-3-3 protein blots. The 
portion of the blot in lanes 8 and 9 was treated with acetic anhydride as described in the text while lanes 10 and 11 were treated with a similar 
amount of acetic acid, as a control. 
peptide against which the antisera were raised. This lysine would also 
have been involved in coupling with glutaraldehlyde. Acetylation of 
this lysine did not prevent recognition of the wild type protein by the 
antisera. As a control, to the other section of the blot, 100~1 of glacial 
acetic acid were added and this part treated as above (but without 
acetic anhydride). 
2.11. Amino acid analysis and protein concentration 
The concentration of the purified proteins was estimated by amino 
acid analysis (on a Beckman 121MB or a Beclanan 6300 Analyser with 
post column ninhydrin detection), or by the Biorad protein concentra- 
tion assay (according to manufacturers instructions). 
3. RESULTS AND DISCUSSION 
Fig. 1 shows western blots of HPLC fractions of 
sheep brain 14-3-3 proteins separated by reverse phase 
HPLC. These were probed with antisera raised against 
peptides corresponding to the p, y, 5, E, r] and T-cell (r) 
isoforms of mammalian 14-3-3 proteins. 
These antisera were quite specific for each isoform 
(with the exception of the & and 6 HPLC peaks - see 
below). There was a low level of cross reaction between 
jI and C antisera. The N-tern&i of these isoforms differ 
only in a Ser+Asn substitution. Nevertheless the amino 
terminal region of 14-3-3 isoforms proved to be a useful 
part of the sequence against which specific antisera 
could be raised. Previously, high titre antibodies have 
proved difficult to obtain against either whole 14-3-3 
proteins or synthetic peptides based on other specific 
regions of the primary structure. Antisera raised against 
a peptide synthesised according to the amino terminal 
region of the o isoform [19,20] did not cross-react with 
any brain isoform, while there was a strong response in 
Western blots to a ca. 30,000 Da protein in cytosolic 
extracts from the epithelial HEp-2 human laryngeal car- 
cinoma cell line at an antibody dilution of ‘/J,ooo (data 
not shown). 
The antiserum raised against the amino terminus of 
the r isoform recognised a minor component eluting 
between the y and 6 peaks. This was a small part of the 
total antigenicity of mixed isoforms from brain while 
the antisera strongly recognised a similar level of recom- 
binant r protein (Fig. 1B). In this case at least some of 
the population of polyclonal antibodies did not require 
the N-acetyl-group, which (like recombinant E 14-3-3) 
was absent. In contrast the E antisera only recognise the 
protein when it is acetylated (Fig. 2) and indicates the 
importance of including the correct structure of a pep- 
tide if the amino-terminal region is used as an epitope 
to raise antibodies. Even the fusion protein is not recog- 
nised although it contains a glycine residue (structurally 
very similar) at the position of the N-acetylation on the 
wild type protein. Recombinant c 14-3-3 (not-N-acetyl- 
ated) is also not recognised by its antiserum (data not 
shown). In the literature there is widespread and incor- 
rect translation of c-DNA sequences into protein se- 
quences without assessing the possible co- or post-trans- 
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AcMDXSELV QXAXLAHQAERYDD MAAAMXAVTEQGHELSNEE NRVISS 
AcTMDXSELVQXAXLAEQAERYDDMAAAMXA VTEQGHELSNEERNLLSVAYXNWGARRSSWRVISS 
AcMDXNELVQXAXLAE QAERYDDMAACMXSVTEQGAELSNENRNLLSVAYXNVVGArrSSWRWSS 
AcMDXNELVQXAXLAE QAERYDDMAACMXSVTEQGAELSNEERNLLSVAYXNVVGARRSSWRWSS 
AcVDRNQLVQXARLAE QANRYDD MAUhMXNVTELNEPLSNNERNLLSVAYXNVVGARRSSWRVISS 
AcMDDREDLVYQAXLAEQAERYDEMVESMXXVAGMDVELTVNHRNLLSVAYXNVIGARRASWRIISS 
AcGDREQLLQRARLAN QAERYDDMlUAMXAVTELNEPLHNNDRNLLSVAYXNWGARRSSWRVISS 
AcMERASLI ~gAsRYrsD~~~~X~ELS~ER~SVA~~~~~SS 
AcMEXTE~I~YDD~TC~VTEQGAE~S~ERNLLSVAYXNW~_SA~VI~ 
66 130 
IEQXTE..RNEXX QMGXEYREXIEAELQDI MXGDY 
IEOKTE..RNEKKQQM~Y~XIEAELQDICNDVLQLY 
IEQXTE..GAEX MXGDY 
IEQXTE..GAgKKQQ~YREXIETELRDICNDVLSLLEKFLIPN~QA..ESXVFYLKMKGDY 
IEQKTSADGNEKKIEMXIE~~AVCQD~SLLDNYLIXNCSETQIESXVFY~GDY 
IEQXEENXGGEDXLXMIREYRQMVETELXLICCDILDVLDXHLIPAANTG..ESXVFYYXMXGDY 
IEQXTMADGNEXXLEXVXAYREXIEXELETVCNDVLALLDXFLIXNCNDFQYESXVFYLXMXGDY 
IEQXSNEEGSEEXGPEVREYRNXVHTELQGVCDTVLGLLDSHLIXEAGDA..ESRVFYLXMXGDY 
IEGXT..DTSD~LQLIXD~S~SI~TTV&EL~DXY~ANATNP..~XVFYLXMXGDY 
131 195 
FRYLSEVASGDNXQTTVSNSQQAYQEAFEIS MQPTHPIRLGLALNFS 
FRYLSEVASGDNKQTmSNS~AYQE~ISKKEMQPTHPIRLGLAtNFSVFYYEILNSPEKACS 
YRYLAEVAAGDDXXGIVDQSQQAYQEAFEISXXEMQPTHPIRLGLALNFSVFYYEILNSPEkA 
YRYLAEVAAGDDXXGIVDQSQQAYQEAFHISXXEMQPTHPIRLGLALNFSVFYYEILNSPEXACS 
YRYLAEVATGEXRATVVESSEXAYSEAHEISXHHMQPTHPIRLGLALNYSVFYYEIQNAPEQACH 
HRYLAEFATGNDRXEAAENSLVAYXAASDIAMTELPPTBP 
YRYLAEVASGEXXNSWEASEAAYXEAFEISXEHMQPTHPIRLGLALNFSVFYYEIQNAPEQACL 
YRYLAEVATGDDXXRIIDSARSAYQEAMDISXXEMPPTNPIRLGLALNFSVFHYEIANSPEEAIS 
FR~~V&Z~DDRXQTIDNSQG&.&.QE&FD~SXXEM~HPIRLGLKLNF~Y~L~~E~CT 
196 257 
WTsENQGDegda 
LAXTAFDEAIAELDTLNEESYXDSTLIMQLLRDNLTLNTSENQGDEGDAGEGEN 
MQLLRDNLTLNTSDTQGDEA 
LAXTAFDEAIAELDTLSEESYXDSTLIMQLLRDNLTLNTSDTQGDEAEAGEGGEN 
LAXTAFDDAIAELDTLNgDSYXDSTLIMQLLRDNLTLNTSDQQDDDG..GEGN 
LAXMFDDAIAELDTLSEESYXDSTLIMQLLRDNLTLNTSDMQGDGEEQNXEALQDVEDENQ 
LAXQAFDDAIAELDTLNEDSYXDSTLIMQLLRDNLTLWTSDQQ.DE.EAGEGN 
LAXTTFDEAMADLHTLSEDSYXDSTLIMQLLRDNLTLNTADNAGEEG..GEAPQEPQS 
&&J&T~E~I&jJZ&DTLNEDSYXDSTLIMQLLRDNLTLN'l!SDSAGEECDAAEGAEN 
Fig. 3(A) Sequence alignment of a and 6 14-3-3 with the other mammalian 14-3-3 isofonn sequences. Residues identical in all known mammalian 
14-3-3 proteins are underlined. Bold characters in the single letter code indicate variable residues within an isoform (see. text for details). Lower 
case letters in the a and S sequences indicate tentative assignments. The sequences are from references [2,3,4,8,10,18,19,20,29,30]. AC denotes 
N-a&y1 group and the threonine suggested as the first residue in the B sequence is shown in italics. (B) Matrix of identities between the sequences 
shown in Fig. 2A. This compares only the identities between the isoforms in the regions that were sequenced for the a and/or S isofotms. This 
also excludes residues that are completely conserved across the range of known 14-3-3 proteins. The figure shows a percentage comparison of 
identical residues for part of the sequence alignment shown in Fig. 2A. 81 residues from the a sequence and 80 residues from the 6 sequence were 
compared to the other isoforms. ‘71 residues from the 6 sequence were compared to a (see Fig. 2A). 
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Fig. 3. (continued) 
lational processing that may occur. This depends on the in addition to having been cloned and sequenced from 
rat, bovine and human species. These are all identical 
in primary structure - which reflects the general high 
level of sequence conservation of each isoform. The 
only sequence variations are Arg112 and Pro’15 in rat c 
while the mammalian 6 sequences from the other species 
have Alall and Ala”‘. In other mammalian 14-3-3 
isoforms that have been sequenced from more than one 
species, bovine and rat 7 contain Ala”‘, Asnla and 
Hisla while these are Ser”* and GlnlU in human q. 
Residue 144 is variable in human 14-3-3 ?I. t is asparag- 
ine according to the cDNA sequenced by Ichimura- 
Ohshima et al. [29] or threonine according to Leffers et 
al. [20]. Human stratifin o 14-3-3 isoform [20] has been 
sequenced in another laboratory and has been named 
HMEl [19]. A variation of Va1247 in the mammary gland 
protein (HMEl) which is Ala247 in stratifin has been 
reported. A possible explanation for the apparent iden- 
tity of 01 and /3 isoforms is that an alternative initiator 
methionine, two codons upstream gives rise to a slightly 
more hydrophobic form. The group of Celis and co- 
workers have cloned and sequenced a 14-3-3 isoform 
(called IEF1054, [20]) which is undoubtedly the human 
equivalent of mammalian 14-3-3 /I. It is identical in 
sequence to bovine p 14-3-3 [30] with the exception of 
Glu”’ in human, Gin”* in bovine) but these authors 
suggest that the upstream methionine codon is the initi- 
ator. Neither of these codons is surrounded by a perfect 
consensus sequence for initiation [31]. Therefore the 
protein starting Ac.MDKSEL.....may be the a isoform 
while the /I isoform commences Ac.TMDKSEL..... In 
these two cases the consensus processing of the initiator 
301 
nature of the residue adjacent o the indicator methion- 
ine. This methionine is generally acetylated, the N-ace- 
tyl-Met may then be removed and the next residue may 
or may not be acetylated [28]. Alternatively an exposed 
glutamine may cyclise to pyroglutamic acid or a glycine 
may be myristoylated (or undergo other fatty acyl mod- 
ification). 
Two of the antisera cross-reacted with two additional 
isoforms that elute at distinct positions on reverse phase 
HPLC. These were a, which is probably identical to B 
isoform and 6 which is probably identical to c isoform. 
Purified preparations of a and 6 isoforms separated by 
reverse-phase HPLC (Fig. 1A) were cleaved with CNBr 
and BNPS-skatole. Peptides fractionated by HPLC 
were analysed by direct protein sequencing and primary 
structures aligned according to 14-3-3 protein [4]. 138 
residues of a 14-3-3 were sequenced and 57 of these are 
absolutely conserved between known mammalian se- 
quences (Fig. 3). Comparison was therefore made with 
the other 81 residues. The matrix (Fig. 3B) was plotted 
from the programme ‘distances’ in the GCG sequence 
analysis programme using modified parameters which 
allows only identical residues to be scored. The figure 
shows the a isoform to be identical to /I in 8 1 out 81 
positions that were compared while the identities be- 
tween other isoforms of 14-3-3 vary from 26 to 66%. 
Similarly, 162 amino acids from 6 14-3-3 were se- 
quenced and 80 residues were compared to the other 
isoforms. There was 100% identity with the c sequence 
but 30 to 66% identity with the other isoforms. The c 
isoform has been sequenced from sheep brain protein 
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Fig. 4. FAB MS of the amino terminal cyanogen bromide peptides 
obtained from y and ?,r isoforms of 14-3-3 protein. By coincidence, 
both have a pseudomolecular ion mass (M+H)+ at 2659 for the ho- 
moserine lactone (Hsl) form. The amino acid analyses (which are quite 
distinct, not shown) clearly prevents confusion as to their identity. The 
peaks at higher mass are sodium and potassium adducts. 
methionine is assumed to be occuring [28,32]. In both 
isoforms on digestion with CNBr a peptide commencing 
KDSEL..... will be formed. In the y and II isoforms, 
with Val and Gly as the second residues, respectively, 
the acetylated initiator methionine undergoes further 
co-translational processing. It is removed and the Val 
and Gly undergo a further round of acetylation. This 
is verified by fast atom bombardment mass spectrome- 
try of the N-terminal CNBr peptides (Fig 4). Since the 
complete amino acid sequence of sheep j? 14-3-3 has not 
yet been determined, the exact molecular weight is un- 
known. However, it is likely to be as highly conserved 
as the counterparts of other isoforms from a range of 
mammalian species. We have determined the sequence 
of peptides corresponding to more than 70% of sheep 
/I 14-3-3 (unpublished results) and can detect no se- 
quence variations from bovine j3 14-3-3 [30]. Electros- 
pray mass spectrometry suggests that the molecular 
weight of sheep /I 14-3-3 is approximately 96 Da higher 
than that of a 14-3-3 (data not shown, the residue 
weight of Thr is 101 .l). Future work will focus on the 
exact structural differences between oY/3 and S/c 
isoforms which may in fact be due to a sub-stoichiomet- 
ric post-translational modification. This could explain 
the ca. 8 min differences in elution position on the shal- 
low HPLC gradient between each pair of proteins. 
The role for N-acetylation of proteins may be protec- 
tion against proteolysis and when proteins have been 
expressed in acetylated or non-acetylated forms the cel- 
lular half life of the former is longer [32]. Whatever the 
biological role for co-translational acetylation, the im- 
portance of taking into account the correct biochemical 
moiety at the amino-terminus of a protein has been 
emphasised by the present findings especially if one 
were to use these antibodies to screen expression librar- 
ies. The antibodies described in the present study will 
be used to probe the location of specific isoforms in 
organelles or sub-cellular distribution of specific 14-3-3 
isoforms. 
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